| Click here to download the DOC | |
Contact:
Julie Dennehy - 508-533-8311
Woburn, MA, June 29, 2005 – Repromedix, the leading national reference laboratory for infertility diagnostics, has added two critical tests to its portfolio of advanced tests for reproductive failure. The new tests are Anti-ß2Glycoprotein I, added to the Antiphospholipid Panel, and Antithrombin Activity, added to the Thrombophilia Panel.
With the addition of the Anti-ß2Glycoprotein I Test, the Repromedix APA Panel sets the standard in helping physicians diagnose patients with complex autoimmune problems, such as Lupus, which can cause pregnancy loss or complications. Anti-ß2Glycoprotein I is one member of the large family of antiphospholipid antibodies that has been significantly linked to pregnancy complications and thrombotic events. Current therapies for helping women with autoimmune disorders to successfully carry a pregnancy to term include low-dose aspirin, subcutaneous unfractionated heparin, or low molecular weight heparin.
Antithrombin Activity (AT, previously known as ATIII) is an essential component of Repromedix’s comprehensive Thrombophilia Panel. In pregnancy, any clotting pathology may be harmful as fetal growth depends on adequate circulation between the mother and the fetus. While women with thrombophilic defects can have normal pregnancies, thrombophilia is considered to be a significant risk factor, and AT deficiency poses the highest risk of all known thrombophilias.
The AT Activity test is indicated for conditions including multiple miscarriage, stillbirth, pre-eclampsia, inter-uterine fetal death, and thrombosis.
If a woman tests positive (abnormal) for Antithrombin Activity, her physician may consider therapeutic regimens of anti-coagulants, including low dose aspirin or low dose molecular weight heparin, or AT concentrates.
About Repromedix
Repromedix is the leading national laboratory specializing in advanced reproductive testing. By taking an interdisciplinary approach to clinical testing, the company helps doctors find solutions to their most difficult cases of female and male infertility, recurrent pregnancy loss, and high-risk pregnancy.
The company, based in Woburn, MA, was founded in 1994 by CEO Craig Sockol. It serves physicians and their patients throughout the United States and Canada.